MiR26-5p inhibits pathological pulmonary microvascular angiogenesis via down-regulating WNT5A

Document Type : Original Article


1 Department of Anesthesiology, People’s Hospital of Chongqing Banan District, Chongqing 401320, China

2 Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, Chongqing 400038, China

3 Southwest Hospital, Third Military Medical University, Chongqing 400038, China

4 Department of Anesthesiology, The Ninth People’s Hospital of Chongqing, Chongqing 400700, China



Objective(s): Pathological micro angiogenesis is a key pathogenic factor in pulmonary diseases such as pulmonary hypertension and hepatopulmonary syndrome. More and more pieces of evidence show that excessive proliferation of pulmonary microvascular endothelial cells is the key event of pathological micro angiogenesis. The purpose of this research is to reveal the mechanism of miR26-5p regulating pulmonary microvascular hyperproliferation.
Materials and Methods: Hepatopulmonary syndrome rat model was made by common bile duct ligation. HE and IHC staining were used for analysis of the pathology of the rat. CCK8, transwell, and wound healing assay were used to assess miR26-5p or target gene WNT5A functioned toward PMVECs. microRNA specific mimics and inhibitors were used for up/down-regulated miR26-5p expression in PMVECs. Recombinant lentivirus was used for overexpression/knockdown WNT5A expression in PMVECs. And the regulation relationship of miR26-5p and WNT5A was analyzed by dual-luciferase reporter assay.
Results: qPCR showed that miR26-5p was significantly down-regulated in the course of HPS disease. Bioinformatics data showed that WNT5A was one of the potential key target genes of miR26-5p. Immunohistochemistry and qPCR analysis showed that WNT5A was largely expressed in pulmonary microvascular endothelial cells, in addition, this molecule was significantly up-regulated with the progression of the disease. Furthermore, dual luciferase reporter assay showed that miR26-5p could bind to WNT5A 3 ‘UTR region to inhibit WNT5A synthesis.
Conclusion: The results suggested MiR26-5p negatively regulated PMVECs proliferation and migration by WNT5A expression. Overexpression of miR26-5p may be a potentially beneficial strategy for HPS therapy.


Main Subjects

1. Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Dig Liver Dis 2011; 43:S8-S14.
2. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32:859-865.
3. Binda E, Visioli A, Giani F, Trivieri N, Palumbo O, Restelli S, et al. Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells.  Cancer Res 2017; 77:996-1007.
4. Mika H, Hirofumi K, Michiko K, Masayuki K, Mikio I, Takao F, et al. Ryk is essential for Wnt-5a-dependent invasiveness in human glioma.  J Biochem 2014;156:29-38.
5. Yang DH, Yoon JY, Lee SH, Bryja V, Andersson ER, Arenas E, et al. Wnt5a is required for endothelial differentiation of embryonic stem cells and vascularization via pathways involving both Wnt/-catenin and protein kinase calpha. Circ Res 2009;104:372-379.
6. Yang X, Zhao S, Yuan H, Shi R, Zhao HJMMR. Knockdown of Ror2 suppresses TNFαinduced inflammation and apoptosis in vascular endothelial cells. Mol Med Rep 2020;22:2981-2989.
7. Shi YN, Zhu N, Liu C, Wu HT, Gui Y, Liao DF, et al. Wnt5a and its signaling pathway in angiogenesis. Clin Chim Acta 2017;471:263-269.
8. Cheng CW, Yeh JC, Fan TP, Smith SK, Charnock-Jones DS. Wnt5a-mediated non-canonical Wnt signalling regulates human endothelial cell proliferation and migration.  Biochem Biophys Res Commun 2008;365:285-290.
9. Masckauchan T, Agalliu D, Vorontchikhina M, Ahn A, Parmalee NL, Li CM, et al. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol Biol Cell 2006;17:5163-5172.
10. Ekstrom EJ, Bergenfelz C, von Bülow V, Serifler F, Carlemalm E, Jonsson GR, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer 2014;13:88-102.
11. Ivey KN, Srivastava D. microRNAs as developmental regulators. cold spring harbor perspectives in biology. Cold Spring Harb Perspect Biol 2015;7:a008144-a008152.
12. Soriano A, Jubierre L, Almazán-Moga A, Molist C, Roma J, Toledo JSD, et al. microRNAs as pharmacological targets in cancer. Pharmacol Res 2013; 75:3-14.
13. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136:215-233.
14. Rajasekaran S, Pattarayan D, Rajaguru P, Sudhakar Gandhi PS, Thimmulappa RK. MicroRNA regulation of acute lung injury and acute respiratory distress syndrome. J Cell Physiol 2016; 231:2097-2106.
15. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 2008; 9:102-114.
16. Chen L, Li YS, Cui J, Ning JN, Wang GS, Qian GS, et al. MiR-206 controls the phenotypic modulation of pulmonary arterial smooth muscle cells induced by serum from rats with hepatopulmonary syndrome by regulating the target gene, annexin A2. Cell Physiol Biochem 2014; 34:1768-1779.
17. Gao J, Chen L, Zeng J, Cui J, Ning JL, Wang GS, et al. The involvement of aquaporin 1 in the hepatopulmonary syndrome rat serum-induced migration of pulmonary arterial smooth muscle cells via the p38-MAPK pathway. Mol Biosyst 2015; 11:3040-3047.
18. Xu D, Gu JT, Yi B, Chen L, Wang GS, Qian GS, et al. Requirement of miR-9-dependent regulation of Myocd in PASMCs phenotypic modulation and proliferation induced by hepatopulmonary syndrome rat serum. J Cell Mol Med 2015; 19:2453-2461.
19. Zhang Y, Pan Y, Xie C. miR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis. Cell Death Dis 2018; 9:777-789.
20. Lin X, Lin BW, Chen XL, Zhang BL, Xiao XJ, Shi JS, et al. PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer. Biochem Biophys Res Commun 2017; 493:1464-1470.
21. Liu C, Gao J, Chen B, Chen L, Belguise K, Yu W, et al. Cyclooxygenase-2 promotes pulmonary intravascular macrophage accumulation by exacerbating BMP signaling in rat experimental hepatopulmonary syndrome. Biochem Pharmacol 2017; 138:205-215.
22. Yang C, Lv K, Chen B, Yang Y, Ai X, Yu H, et al. miR144-3p inhibits PMVECs excessive proliferation in angiogenesis of hepatopulmonary syndrome via Tie2. Exp Cell Res 2018; 365:24-32.
23. Yang C, Lv K, Chen B, Yang Y, Ai X, Yu H, et al. miR144-3p inhibits PMVECs excessive proliferation in angiogenesis of hepatopulmonary syndrome via Tie2. Exp Cell Res 2018; 365:24-32.
24. Yang C, Lin Y, Liu H, Shen G, Luo J, Zhang H, et al. The broad complex isoform 2 (BrC-Z2) transcriptional factor plays a critical role in vitellogenin transcription in the silkworm Bombyx mori. Biochim Biophys Acta 2014; 1840:2674-2684.
25. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41:1122-1129.
26. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135:1168-1175.
27. Grace JA, Angus PW. Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol 2013; 28:213-219.
28. Jain KG, Zhao R, Liu Y, Guo X, Yi G, Ji HL. Wnt5a/b-catenin axis is involved in the downregulation of AT2 lineage by PAI-1. Am J Physiol Lung Cell Mol Physiol 2022;323:L515-L524.
29. Halmetoja E, Nagy I, Szabo Z, Alakoski T, Yrjölä R, Vainio L, et al. Wnt11 in regulation of physiological and pathological cardiac growth. FASEB J 2022; 36:e22544-22560.
30. Bueno MLP, Saad STO, Roversi FM. WNT5A in tumor development and progression: A comprehensive review. Biomed Pharmacother 2022;155:113599-113616.
31. Ding N, Zheng C. Secreted frizzled-related protein 5 promotes angiogenesis of human umbilical vein endothelial cells and alleviates myocardial injury in diabetic mice with myocardial infarction by inhibiting Wnt5a/JNK signaling. Bioengineered 2022; 13:11656-11667.
32. de Lucia C, Komici K, Borghetti G, Femminella GD, Bencivenga L, Cannavo A, et al. microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases. Front Med (Lausanne) 2017; 4:74-93.
33. Perez-Cremades D, Mompeon A, Vidal-Gomez X, Hermenegildo C, Novella S. Role of miRNA in the regulatory mechanisms of estrogens in cardiovascular ageing. Oxid Med Cell Longev 2018; 2018:6082387-6082402.
34. Wang L, Zhuang L, Rong H, Guo Y, Ling X, Wang R, et al. MicroRNA-101 inhibits proliferation of pulmonary microvascular endothelial cells in a rat model of hepatopulmonary syndrome by targeting the JAK2/STAT3 signaling pathway. Mol Med Rep 2015; 12:8261-8267.